Supernus Pharma has two phase III trials showing its attention-deficit hyperactivity disorder (ADHD) drug SPN-812 met its objectives, but still saw its shares fall as investors digested the data.
Shire has refiled its experimental attention deficit hyperactivity disorder drug SHP 465 in the US, having garnered new data further backing its safety and efficacy.